IS3030B - Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu - Google Patents

Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu

Info

Publication number
IS3030B
IS3030B IS8077A IS8077A IS3030B IS 3030 B IS3030 B IS 3030B IS 8077 A IS8077 A IS 8077A IS 8077 A IS8077 A IS 8077A IS 3030 B IS3030 B IS 3030B
Authority
IS
Iceland
Prior art keywords
macrocylic
antiproliferative agents
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
IS8077A
Other languages
English (en)
Other versions
IS8077A (is
Inventor
Eddy Freyne
Timothy Perera
Peter Buijnsters
Marc Willems
Gaston Marvella
Werner EMBRECHTS
Peter Holte
Frederk Rombouts
Carsten Schulz-Fademrecht
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33493782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS3030(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IS8077A publication Critical patent/IS8077A/is
Publication of IS3030B publication Critical patent/IS3030B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS8077A 2003-05-27 2005-10-14 Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu IS3030B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP0305723 2003-05-27
EP0310266 2003-09-15
EP0351061 2003-12-18
PCT/EP2004/005621 WO2004105765A1 (en) 2003-05-27 2004-05-25 Macrocyclic quinazoline derivatives as antiproliferative agents

Publications (2)

Publication Number Publication Date
IS8077A IS8077A (is) 2005-10-14
IS3030B true IS3030B (is) 2021-06-15

Family

ID=33493782

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8077A IS3030B (is) 2003-05-27 2005-10-14 Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu

Country Status (31)

Country Link
US (4) US7648975B2 (is)
EP (2) EP1633365B1 (is)
JP (1) JP4887151B2 (is)
KR (1) KR101143878B1 (is)
CN (1) CN102718775B (is)
AR (2) AR045687A1 (is)
AT (1) ATE544454T1 (is)
AU (1) AU2004243487B2 (is)
BR (1) BRPI0410714B8 (is)
CA (1) CA2525214C (is)
CL (1) CL2004001267A1 (is)
CO (1) CO5640038A2 (is)
CY (1) CY1113002T1 (is)
DK (1) DK1633365T3 (is)
EA (1) EA009064B1 (is)
ES (1) ES2381976T3 (is)
HR (1) HRP20120351T1 (is)
IL (3) IL172154A0 (is)
IS (1) IS3030B (is)
JO (1) JO2785B1 (is)
MX (1) MXPA05012762A (is)
MY (1) MY148633A (is)
NO (1) NO334209B1 (is)
NZ (1) NZ544154A (is)
PA (1) PA8603801A1 (is)
PL (1) PL1633365T3 (is)
PT (1) PT1633365E (is)
SI (1) SI1633365T1 (is)
TW (3) TWI468372B (is)
UA (1) UA84010C2 (is)
WO (1) WO2004105765A1 (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
CA2545711A1 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
EP1697384B1 (en) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
ES2335216T3 (es) 2003-12-18 2010-03-23 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolina con actividad antiproliferativa.
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
DK1854789T3 (da) 2005-02-23 2013-10-21 Shionogi & Co Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8778919B2 (en) * 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
EP2044084B1 (en) * 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
JP2009242240A (ja) * 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
EP2061469B8 (en) * 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス，インコーポレイテッド 亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター
AU2007310842A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Use of a MT kinase inhibitor for treating or preventing brain cancer
WO2008049930A2 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv A method for profiling kinase inhibitors
EA200970420A1 (ru) * 2006-10-27 2009-12-30 Янссен Фармацевтика Нв Применение mtki 1 для лечения или предупреждения рака кости
MX2009004436A (es) * 2006-10-27 2009-05-22 Janssen Pharmaceutica Nv Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3.
JPWO2008087736A1 (ja) * 2007-01-19 2010-05-06 宇部興産株式会社 アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI406853B (zh) * 2010-04-07 2013-09-01 Dev Center Biotechnology Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
RU2735545C2 (ru) * 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
LT2822953T (lt) * 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
KR101927114B1 (ko) * 2014-02-07 2018-12-10 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
EP3218380B1 (en) 2014-11-16 2021-03-17 Array Biopharma, Inc. Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
PT3423113T (pt) 2016-02-29 2020-12-10 Oncodesign Sa Inibidor de egfr macrocíclico radiomarcado
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
MX2020005927A (es) 2017-12-07 2020-10-07 Amplyx Pharmaceuticals Inc Agentes antifunales derivados de piridina heterociclica sustituida.
US11771688B2 (en) 2018-06-25 2023-10-03 Amplyx Pharmaceuticals, Inc. Pyridine derivatives substituted by heterocyclic ring and amino group
WO2021152165A1 (en) * 2020-01-31 2021-08-05 Oncodesign S.A. Macrocyclic rip2-kinase inhibitors
WO2021216440A1 (en) * 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
IL313548A (en) 2021-12-16 2024-08-01 Kinnate Biopharma Inc MET kinase inhibitors
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途
WO2026008023A1 (zh) * 2024-07-04 2026-01-08 正大天晴药业集团股份有限公司 哒嗪胺类化合物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (is) * 1956-06-11
DE2423536A1 (de) * 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4126688A (en) 1976-05-17 1978-11-21 Janssen Pharmaceutica N.V. Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
HU228446B1 (en) * 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DK1117653T3 (da) * 1998-10-01 2003-05-26 Astrazeneca Ab Quinolin- og quinazolinderivater og deres anvendelse som inhibitorer af cykokin-merierede sygdomme
FR2809400B1 (fr) * 2000-05-25 2004-04-09 Inst Francais Du Petrole Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف

Also Published As

Publication number Publication date
HK1176350A1 (zh) 2013-07-26
TW200510431A (en) 2005-03-16
JP2007504276A (ja) 2007-03-01
IL172154A0 (en) 2006-04-10
CA2525214C (en) 2012-11-27
TW201245111A (en) 2012-11-16
IL233046A0 (en) 2014-07-31
CN102718775B (zh) 2016-02-17
ES2381976T3 (es) 2012-06-04
US7648975B2 (en) 2010-01-19
ATE544454T1 (de) 2012-02-15
NZ544154A (en) 2009-01-31
CA2525214A1 (en) 2004-12-09
CY1113002T1 (el) 2016-04-13
BRPI0410714B1 (pt) 2019-09-24
MXPA05012762A (es) 2006-02-13
EP2305687A1 (en) 2011-04-06
EA009064B1 (ru) 2007-10-26
BRPI0410714B8 (pt) 2021-05-25
IL233045B (en) 2018-07-31
KR20060014415A (ko) 2006-02-15
IS8077A (is) 2005-10-14
HRP20120351T1 (hr) 2012-05-31
AU2004243487A1 (en) 2004-12-09
AR092137A2 (es) 2015-03-25
CL2004001267A1 (es) 2005-04-22
EP1633365B1 (en) 2012-02-08
US20130178624A1 (en) 2013-07-11
US20160207938A1 (en) 2016-07-21
JP4887151B2 (ja) 2012-02-29
KR101143878B1 (ko) 2012-05-24
PT1633365E (pt) 2012-05-07
TWI379835B (en) 2012-12-21
DK1633365T3 (da) 2012-05-14
BRPI0410714A (pt) 2006-06-13
EA200501866A1 (ru) 2006-06-30
WO2004105765A1 (en) 2004-12-09
US9273013B2 (en) 2016-03-01
IL233045A0 (en) 2014-07-31
PL1633365T3 (pl) 2012-07-31
CO5640038A2 (es) 2006-05-31
AR045687A1 (es) 2005-11-09
NO20056196L (no) 2005-12-28
PA8603801A1 (es) 2004-12-16
TWI468397B (zh) 2015-01-11
EP1633365A1 (en) 2006-03-15
US8394786B2 (en) 2013-03-12
CN102718775A (zh) 2012-10-10
NO334209B1 (no) 2014-01-13
MY148633A (en) 2013-05-15
SI1633365T1 (sl) 2012-06-29
US20100105668A1 (en) 2010-04-29
TW201245160A (en) 2012-11-16
AU2004243487B2 (en) 2009-12-03
TWI468372B (zh) 2015-01-11
JO2785B1 (en) 2014-03-15
US20060247237A1 (en) 2006-11-02
UA84010C2 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
IS3030B (is) Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu
IL174533A0 (en) Quinazoline derivatives as antiproliferative agents
IL174534A0 (en) Quinazoline derivatives
GB0321648D0 (en) Quinazoline derivatives
ZA200602264B (en) Quinazoline derivatives
IL174257A0 (en) Quinazoline derivatives
GB0215823D0 (en) Quinazoline derivatives
SI1847539T1 (sl) Kinazolinski derivati
PL378245A1 (pl) Pochodne pirolopirydazyny
GB0317665D0 (en) Qinazoline derivatives
PL1682493T3 (pl) Pochodne amidoacetonitrylu
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
IL174390A0 (en) Quinazoline derivatives
GB0326459D0 (en) Quinazoline derivatives
GB0330002D0 (en) Quinazoline derivatives
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PL1706373T3 (pl) Pochodne amidoacetonitrylu
ZA200603039B (en) Quinazoline derivatives
PL374817A1 (en) Quinazoline derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0321620D0 (en) Quinazoline derivatives
HK1091203A (en) Quinazoline derivatives as antiproliferative agents
GB0317664D0 (en) Quinazoline derivatives
GB0322458D0 (en) Quinazoline derivatives
GB0322536D0 (en) Quinazoline derivatives